GO vs. non-GO therapy offers better survival but with higher toxicity in AML and high-risk MDS

Key clinical point: Gemtuzumab ozogamicin (GO) showed superior survival outcomes in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) than non-GO therapy, but higher dose increased the risk for early death.

Major finding: GO vs. non-GO arm showed improved overall survival (hazard ratio [HR], 0.86; P = .003), event-free survival (HR, 0.86; P = .015), and relapse-free survival (HR, 0.83; P = .001). However, GO vs. non-GO was associated with an increased risk for early death at a dose of 6 mg/m² or higher (relative risk [RR] 2.01; P = .005), hepatic-related adverse effects (RR 1.29; P = .02), and bleeding (RR 1.13; P = .018).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials and 15 retrospective studies that compared GO (n = 4,768) with non-GO (n = 6,466) therapies in 11,234 patients with AML (n = 11,105) and high-risk MDS (n = 129).

Disclosures: This study was supported by the Chinese National Major Project for New Drug Innovation, the National Natural Science Foundation of China, Shenzhen Science and Technology Foundation, and Shenzhen Key Laboratory Foundation. The authors declared no conflicts of interest.

Source: Xu Q et al. Front Immunol. 2021 Aug 16. doi: 10.3389/fimmu.2021.683595.

Key clinical point: Gemtuzumab ozogamicin (GO) showed superior survival outcomes in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) than non-GO therapy, but higher dose increased the risk for early death.

Major finding: GO vs. non-GO arm showed improved overall survival (hazard ratio [HR], 0.86; P = .003), event-free survival (HR, 0.86; P = .015), and relapse-free survival (HR, 0.83; P = .001). However, GO vs. non-GO was associated with an increased risk for early death at a dose of 6 mg/m² or higher (relative risk [RR] 2.01; P = .005), hepatic-related adverse effects (RR 1.29; P = .02), and bleeding (RR 1.13; P = .018).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials and 15 retrospective studies that compared GO (n = 4,768) with non-GO (n = 6,466) therapies in 11,234 patients with AML (n = 11,105) and high-risk MDS (n = 129).

Disclosures: This study was supported by the Chinese National Major Project for New Drug Innovation, the National Natural Science Foundation of China, Shenzhen Science and Technology Foundation, and Shenzhen Key Laboratory Foundation. The authors declared no conflicts of interest.

Source: Xu Q et al. Front Immunol. 2021 Aug 16. doi: 10.3389/fimmu.2021.683595.

Key clinical point: Gemtuzumab ozogamicin (GO) showed superior survival outcomes in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) than non-GO therapy, but higher dose increased the risk for early death.

Major finding: GO vs. non-GO arm showed improved overall survival (hazard ratio [HR], 0.86; P = .003), event-free survival (HR, 0.86; P = .015), and relapse-free survival (HR, 0.83; P = .001). However, GO vs. non-GO was associated with an increased risk for early death at a dose of 6 mg/m² or higher (relative risk [RR] 2.01; P = .005), hepatic-related adverse effects (RR 1.29; P = .02), and bleeding (RR 1.13; P = .018).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials and 15 retrospective studies that compared GO (n = 4,768) with non-GO (n = 6,466) therapies in 11,234 patients with AML (n = 11,105) and high-risk MDS (n = 129).

Disclosures: This study was supported by the Chinese National Major Project for New Drug Innovation, the National Natural Science Foundation of China, Shenzhen Science and Technology Foundation, and Shenzhen Key Laboratory Foundation. The authors declared no conflicts of interest.

Source: Xu Q et al. Front Immunol. 2021 Aug 16. doi: 10.3389/fimmu.2021.683595.